The National Institute for Health and Care Excellence (NICE) has recommended the first drug for NHS use to prevent cisplatin-induced hearing loss (ototoxicity) in children and young people between the ages of one month and 17 years old. Pedmarqsi ® (anhydrous sodium thiosulfate) is indicated for these children who have localised, non-metastatic, solid tumours.